Wellington, NZ, 3rd November 2016: Volpara Health Technologies (“Volpara”; ASX:VHT), a digital health company focused on early detection of breast cancer by improving quality of screening, has today advised that the United States Food and Drug Administration has launched the EQUIP initiative, “Enhancing Quality Using the Inspection Program”.
The program, which was launched on 27th October 2016 to coincide with the 25th anniversary of the passage of the Mammography Quality Standards Act (MQSA), is designed to emphasise “the need for ongoing facility review of clinical image quality”. From 1st January 2017, three new
questions to ensure compliance with regulations relating to quality assurance will be addressed in the FDA’s annual facility inspections of the approximately 8,744 accredited breast screening providers across the United States.
For further information please download PDF attached:
Download this document
